Top

Published in:

01-02-2017 | Invited Review

Tubular and genetic disorders associated with kidney stones

Authors: Nilufar Mohebbi, Pietro Manuel Ferraro, Giovanni Gambaro, Robert Unwin

Published in: Urolithiasis | Issue 1/2017

Abstract

This concise review summarizes our current understanding and the recent developments in genetics and related renal tubular disorders that have been linked with, or have been shown to be causal in, renal stone disease. The aim is to provide a readily accessible quick and easy update for urologists, nephrologists and endocrine or metabolic physicians whose practice involves the diagnosis and management of nephrolithiasis. An important message is to always consider a seemingly rare, and usually genetic, cause of kidney stones, since some of these are emerging as more common than originally thought, especially in adult clinical practice in which a family history of stones is a common finding.

Scales CD Jr, Smith AC, Hanley JM, Saigal CS (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165. doi:10.1016/j.eururo.2012.03.052 PubMedPubMedCentralCrossRef

Gee HY, Jun I, Braun DA, Lawson JA, Halbritter J, Shril S, Nelson CP, Tan W, Stein D, Wassner AJ, Ferguson MA, Gucev Z, Sayer JA, Milosevic D, Baum M, Tasic V, Lee MG, Hildebrandt F (2016) Mutations in SLC26A1 cause nephrolithiasis. Am J Hum Genet 98(6):1228–1234. doi:10.1016/j.ajhg.2016.03.026 PubMedPubMedCentralCrossRef

Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F (2015) Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551. doi:10.1681/ASN.2014040388 PubMedCrossRef

Claes DJ, Jackson E (2012) Cystinuria: mechanisms and management. Pediatr Nephrol 27(11):2031–2038. doi:10.1007/s00467-011-2092-6 PubMedCrossRef

Saravakos P, Kokkinou V, Giannatos E (2014) Cystinuria: current diagnosis and management. Urology 83(4):693–699. doi:10.1016/j.urology.2013.10.013 PubMedCrossRef

Dello Strologo L, Rizzoni G (2006) Cystinuria. Acta Paediatr Suppl 95(452):31–33. doi:10.1080/08035320600649473 CrossRef

Cassidy MJ, McCulloch T, Fairbanks LD, Simmonds HA (2004) Diagnosis of adenine phosphoribosyltransferase deficiency as the underlying cause of renal failure in a renal transplant recipient. Nephrol Dial Transplant 19(3):736–738PubMedCrossRef

Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T (2001) Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland. Am J Kidney Dis 38(3):473–480PubMedCrossRef

Mohebbi NWCA (2015) Inherited forms of distal renal tubular acidosis. Der Nephrologe. doi:10.1007/s11560-014-0946-1

10.

Stehberger PA, Schulz N, Finberg KE, Karet FE, Giebisch G, Lifton RP, Geibel JP, Wagner CA (2003) Localization and regulation of the ATP6V0A4 (a4) vacuolar H+-ATPase subunit defective in an inherited form of distal renal tubular acidosis. J Am Soc Nephrol 14(12):3027–3038PubMedCrossRef

11.

Dhayat NA, Schaller A, Albano G, Poindexter J, Griffith C, Pasch A, Gallati S, Vogt B, Moe OW, Fuster DG (2016) The vacuolar H+-ATPase B1 subunit polymorphism p. E161K associates with impaired urinary acidification in recurrent stone formers. J Am Soc Nephrol 27(5):1544–1554. doi:10.1681/ASN.2015040367 PubMedCrossRef

12.

Mohebbi N, Vargas-Poussou R, Hegemann SC, Schuknecht B, Kistler AD, Wuthrich RP, Wagner CA (2013) Homozygous and compound heterozygous mutations in the ATP6V1B1 gene in patients with renal tubular acidosis and sensorineural hearing loss. Clin Genet 83(3):274–278. doi:10.1111/j.1399-0004.2012.01891.x PubMedCrossRef

13.

Hennings JC, Picard N, Huebner AK, Stauber T, Maier H, Brown D, Jentsch TJ, Vargas-Poussou R, Eladari D, Hubner CA (2012) A mouse model for distal renal tubular acidosis reveals a previously unrecognized role of the V-ATPase a4 subunit in the proximal tubule. EMBO Mol Med 4(10):1057–1071. doi:10.1002/emmm.201201527 PubMedPubMedCentralCrossRef

14.

Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkaloglu A, Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, Cunningham MJ, Jha V, Lifton RP (1999) Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 21(1):84–90. doi:10.1038/5022 PubMedCrossRef

15.

Wagner CA, Devuyst O, Bourgeois S, Mohebbi N (2009) Regulated acid-base transport in the collecting duct. Pflugers Arch 458(1):137–156. doi:10.1007/s00424-009-0657-z PubMedCrossRef

16.

Khositseth S, Sirikanaerat A, Khoprasert S, Opastirakul S, Kingwatanakul P, Thongnoppakhun W, Yenchitsomanus PT (2008) Hematological abnormalities in patients with distal renal tubular acidosis and hemoglobinopathies. Am J Hematol 83(6):465–471. doi:10.1002/ajh.21151 PubMedCrossRef

17.

Batlle D, Haque SK (2012) Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant 27(10):3691–3704. doi:10.1093/ndt/gfs442 PubMedCrossRef

18.

Hu PY, Roth DE, Skaggs LA, Venta PJ, Tashian RE, Guibaud P, Sly WS (1992) A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries. Hum Mutat 1(4):288–292. doi:10.1002/humu.1380010404 PubMedCrossRef

19.

Ismail EA, Abul Saad S, Sabry MA (1997) Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome. Eur J Pediatr 156(12):957–962PubMedCrossRef

20.

Haque SK, Ariceta G, Batlle D (2012) Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant 27(12):4273–4287. doi:10.1093/ndt/gfs493 PubMedPubMedCentralCrossRef

21.

Biber J, Murer H, Mohebbi N, Wagner CA (2014) Renal handling of phosphate and sulfate. Compr Physiol 4(2):771–792. doi:10.1002/cphy.c120031 PubMedCrossRef

22.

Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Juppner H (2006) SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 78(2):179–192. doi:10.1086/499409 PubMedCrossRef

23.

Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D, Hochberg Z, Strom TM (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78(2):193–201. doi:10.1086/499410 PubMedCrossRef

24.

Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, Hanley DA, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Savendahl L, Munns CF, Lee H, Juppner H, Bergwitz C (2014) Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol 25(10):2366–2375. doi:10.1681/ASN.2013101085 PubMedPubMedCentralCrossRef

25.

Arcidiacono T, Mingione A, Macrina L, Pivari F, Soldati L, Vezzoli G (2014) Idiopathic calcium nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies. Am J Nephrol 40(6):499–506. doi:10.1159/000369833 PubMed

26.

Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347(13):983–991. doi:10.1056/NEJMoa020028 PubMedCrossRef

27.

Wagner CA, Rubio-Aliaga I, Biber J, Hernando N (2014) Genetic diseases of renal phosphate handling. Nephrol Dial Transplant 29(Suppl 4):iv45–54. doi:10.1093/ndt/gfu217

28.

Magen D, Berger L, Coady MJ, Ilivitzki A, Militianu D, Tieder M, Selig S, Lapointe JY, Zelikovic I, Skorecki K (2010) A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 362(12):1102–1109. doi:10.1056/NEJMoa0905647 PubMedCrossRef

29.

Virkki LV, Forster IC, Hernando N, Biber J, Murer H (2003) Functional characterization of two naturally occurring mutations in the human sodium-phosphate cotransporter type IIa. J Bone Miner Res 18(12):2135–2141. doi:10.1359/jbmr.2003.18.12.2135 PubMedCrossRef

30.

Lapointe JY, Tessier J, Paquette Y, Wallendorff B, Coady MJ, Pichette V, Bonnardeaux A (2006) NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 69(12):2261–2267. doi:10.1038/sj.ki.5000437 PubMedCrossRef

31.

Dinour D, Davidovits M, Ganon L, Ruminska J, Forster IC, Hernando N, Eyal E, Holtzman EJ, Wagner CA (2016) Loss of function of NaPiIIa causes nephrocalcinosis and possibly kidney insufficiency. Pediatr Nephrol. doi:10.1007/s00467-016-3443-0 PubMed

32.

Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H, Wingen AM, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M (2011) Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365(5):410–421. doi:10.1056/NEJMoa1103864 PubMedCrossRef

33.

Colussi G, Ganon L, Penco S, De Ferrari ME, Ravera F, Querques M, Primignani P, Holtzman EJ, Dinour D (2014) Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure. Nephrol Dial Transplant 29(3):636–643. doi:10.1093/ndt/gft460 PubMedCrossRef

34.

Ferraro PM, Minucci A, Primiano A, De Paolis E, Gervasoni J, Persichilli S, Naticchia A, Capoluongo E, Gambaro G (2016) A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass. Urolithiasis. doi:10.1007/s00240-016-0923-4

35.

Gigante M, Santangelo L, Diella S, Caridi G, Argentiero L, D’’Alessandro MM, Martino M, Stea ED, Ardissino G, Carbone V, Pepe S, Scrutinio D, Maringhini S, Ghiggeri GM, Grandaliano G, Giordano M, Gesualdo L (2016) Mutational spectrum of CYP24A1 gene in a cohort of italian patients with idiopathic infantile hypercalcemia. Nephron 133(3):193–204. doi:10.1159/000446663 PubMedCrossRef

36.

Nesterova G, Malicdan MC, Yasuda K, Sakaki T, Vilboux T, Ciccone C, Horst R, Huang Y, Golas G, Introne W, Huizing M, Adams D, Boerkoel CF, Collins MT, Gahl WA (2013) 1,25-(OH)2D-24 Hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol 8(4):649–657. doi:10.2215/CJN.05360512 PubMedPubMedCentralCrossRef

37.

Vargas-Poussou R, Mansour-Hendili L, Baron S, Bertocchio JP, Travers C, Simian C, Treard C, Baudouin V, Beltran S, Broux F, Camard O, Cloarec S, Cormier C, Debussche X, Dubosclard E, Eid C, Haymann JP, Kiando SR, Kuhn JM, Lefort G, Linglart A, Lucas-Pouliquen B, Macher MA, Maruani G, Ouzounian S, Polak M, Requeda E, Robier D, Silve C, Souberbielle JC, Tack I, Vezzosi D, Jeunemaitre X, Houillier P (2016) Familial Hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism: similarities and differences. J Clin Endocrinol Metab 101(5):2185–2195. doi:10.1210/jc.2015-3442 PubMedCrossRef

38.

Stratta P, Merlotti G, Musetti C, Quaglia M, Pagani A, Izzo C, Radin E, Airoldi A, Baorda F, Palladino T, Leone MP, Guarnieri V (2014) Calcium-sensing-related gene mutations in hypercalcaemic hypocalciuric patients as differential diagnosis from primary hyperparathyroidism: detection of two novel inactivating mutations in an Italian population. Nephrol Dial Transplant 29(10):1902–1909. doi:10.1093/ndt/gfu065 PubMedCrossRef

39.

Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335(15):1115–1122. doi:10.1056/NEJM199610103351505 PubMedCrossRef

40.

Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjornsson G, Haraldsdottir E, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Masson G, Holm H, Gudbjartsson DF, Thorsteinsdottir U, Indridason OS, Palsson R, Stefansson K (2015) Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 6:7975. doi:10.1038/ncomms8975 PubMedPubMedCentralCrossRef

41.

Vezzoli G, Terranegra A, Aloia A, Arcidiacono T, Milanesi L, Mosca E, Mingione A, Spotti D, Cusi D, Hou J, Hendy GN, Soldati L, Paloschi V, Dogliotti E, Brasacchio C, Dell’Antonio G, Montorsi F, Bertini R, Bellinzoni P, Guazzoni G, Borghi L, Guerra A, Allegri F, Ticinesi A, Meschi T, Nouvenne A, Lupo A, Fabris A, Gambaro G, Strazzullo P, Rendina D, De Filippo G, Brandi ML, Croppi E, Cianferotti L, Trinchieri A, Caudarella R, Cupisti A, Anglani F, Del Prete D (2013) Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 is associated with calcium nephrolithiasis. J Clin Endocrinol Metab 98(9):3839–3847. doi:10.1210/jc.2013-1834 PubMedPubMedCentralCrossRef

42.

Vezzoli G, Terranegra A, Rainone F, Arcidiacono T, Cozzolino M, Aloia A, Dogliotti E, Cusi D, Soldati L (2011) Calcium-sensing receptor and calcium kidney stones. J Transl Med 9:201. doi:10.1186/1479-5876-9-201 PubMedPubMedCentralCrossRef

43.

Windpessl M, Ritelli M, Wallner M, Colombi M (2016) A novel homozygous SLC2A9 mutation associated with renal-induced hypouricemia. Am J Nephrol 43(4):245–250. doi:10.1159/000445845 PubMedCrossRef

44.

Mou LJ, Jiang LP, Hu Y (2015) A novel homozygous GLUT9 mutation cause recurrent exercise-induced acute renal failure and posterior reversible encephalopathy syndrome. J Nephrol 28(3):387–392. doi:10.1007/s40620-014-0073-0 PubMedCrossRef

45.

Nishida H, Kaida H, Ishibashi M, Baba K, Kouno K, Okuda S (2005) Evaluation of exercise-induced acute renal failure in renal hypouricemia using Tc-99m DTPA renography. Ann Nucl Med 19(4):325–329PubMedCrossRef

46.

Bhasin B, Stiburkova B, De Castro-Pretelt M, Beck N, Bodurtha JN, Atta MG (2014) Hereditary renal hypouricemia: a new role for allopurinol? Am J Med 127(1):e3–e4. doi:10.1016/j.amjmed.2013.08.025 PubMedCrossRef

47.

Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B, Scheinman SJ, Harding B, Bolino A, Devoto M, Goodyer P, Rigden SP, Wrong O, Jentsch TJ, Craig IW, Thakker RV (1996) A common molecular basis for three inherited kidney stone diseases. Nature 379(6564):445–449. doi:10.1038/379445a0 PubMedCrossRef

48.

Devuyst O, Christie PT, Courtoy PJ, Beauwens R, Thakker RV (1999) Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent’s disease. Hum Mol Genet 8(2):247–257PubMedCrossRef

49.

Copelovitch L, Nash MA, Kaplan BS (2007) Hypothesis: dent disease is an underrecognized cause of focal glomerulosclerosis. Clin J Am Soc Nephrol 2(5):914–918. doi:10.2215/CJN.00900207 PubMedCrossRef

50.

Wrong OM, Norden AG, Feest TG (1994) Dent’s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM 87(8):473–493PubMed

51.

De Leo MG, Staiano L, Vicinanza M, Luciani A, Carissimo A, Mutarelli M, Di Campli A, Polishchuk E, Di Tullio G, Morra V, Levtchenko E, Oltrabella F, Starborg T, Santoro M, di Bernardo D, Devuyst O, Lowe M, Medina DL, Ballabio A, De Matteis MA (2016) Autophagosome-lysosome fusion triggers a lysosomal response mediated by TLR9 and controlled by OCRL. Nat Cell Biol 18(8):839–850. doi:10.1038/ncb3386 PubMedPubMedCentralCrossRef

52.

Blanchard A, Vargas-Poussou R, Peyrard S, Mogenet A, Baudouin V, Boudailliez B, Charbit M, Deschesnes G, Ezzhair N, Loirat C, Macher MA, Niaudet P, Azizi M (2008) Effect of hydrochlorothiazide on urinary calcium excretion in dent disease: an uncontrolled trial. Am J Kidney Dis 52(6):1084–1095. doi:10.1053/j.ajkd.2008.08.021 PubMedCrossRef

53.

Cebotaru V, Kaul S, Devuyst O, Cai H, Racusen L, Guggino WB, Guggino SE (2005) High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent’s disease. Kidney Int 68(2):642–652. doi:10.1111/j.1523-1755.2005.00442.x PubMedCrossRef

54.

Yu AS (2015) Claudins and the kidney. J Am Soc Nephrol 26(1):11–19. doi:10.1681/ASN.2014030284 PubMedCrossRef

55.

Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, Sulem P, Halldorsson BV, de Vegt F, d’Ancona FC, den Heijer M, Franzson L, Christiansen C, Alexandersen P, Rafnar T, Kristjansson K, Sigurdsson G, Kiemeney LA, Bodvarsson M, Indridason OS, Palsson R, Kong A, Thorsteinsdottir U, Stefansson K (2009) Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41(8):926–930. doi:10.1038/ng.404 PubMedCrossRef

56.

Toka HR, Genovese G, Mount DB, Pollak MR, Curhan GC (2013) Frequency of rare allelic variation in candidate genes among individuals with low and high urinary calcium excretion. PLoS One 8(8):e71885. doi:10.1371/journal.pone.0071885 PubMedPubMedCentralCrossRef

57.

Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12(9):1872–1881PubMed

58.

Yamaguti PM, Neves FA, Hotton D, Bardet C, de La Dure-Molla M, Castro LC, Scher MD, Barbosa ME, Ditsch C, Fricain JC, de La Faille R, Figueres ML, Vargas-Poussou R, Houiller P, Chaussain C, Babajko S, Berdal A, Acevedo AC (2016) Amelogenesis imperfecta in familial hypomagnesaemia and hypercalciuria with nephrocalcinosis caused by CLDN19 gene mutations. J Med Genet. doi:10.1136/jmedgenet-2016-103956 PubMed

59.

Praga M, Vara J, Gonzalez-Parra E, Andres A, Alamo C, Araque A, Ortiz A, Rodicio JL (1995) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 47(5):1419–1425PubMedCrossRef

60.

Zimmermann B, Plank C, Konrad M, Stohr W, Gravou-Apostolatou C, Rascher W, Dotsch J (2006) Hydrochlorothiazide in CLDN16 mutation. Nephrol Dial Transplant 21(8):2127–2132. doi:10.1093/ndt/gfl144 PubMedCrossRef

61.

Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8(8):467–475. doi:10.1038/nrneph.2012.113 PubMedCrossRef

62.

Pelle A, Cuccurullo A, Mancini C, Sebastiano R, Stallone G, Negrisolo S, Benetti E, Peruzzi L, Petrarulo M, De Marchi M, Marangella M, Amoroso A, Giachino D, Mandrile G (2016) Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria. J Nephrol. doi:10.1007/s40620-016-0287-4 PubMed

63.

Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol 9(3):468–477. doi:10.2215/CJN.06820613 PubMedPubMedCentralCrossRef

64.

Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369(7):649–658. doi:10.1056/NEJMra1301564 PubMedCrossRef

65.

Filler G, Hoppe B (2014) Combined liver-kidney transplantation for hyperoxaluria type II? Pediatr Transplant 18(3):237–239. doi:10.1111/petr.12243 PubMedCrossRef

66.

Naderi G, Latif A, Tabassomi F, Esfahani ST (2014) Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. Pediatr Transplant 18(3):E69–E73. doi:10.1111/petr.12240 PubMedCrossRef

67.

Hoppe B (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. Nephrol Dial Transplant 27(8):3024–3026. doi:10.1093/ndt/gfs308 PubMedCrossRef

68.

Williams EL, Bockenhauer D, van’t Hoff WG, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 27(8):3191–3195. doi:10.1093/ndt/gfs039 PubMedCrossRef

69.

Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11(1):119–126. doi:10.2215/CJN.02810315 PubMedCrossRef

70.

Lu X, Sun D, Xu B, Pan J, Wei Y, Mao X, Yu D, Liu H, Gao B (2016) In silico screening and molecular dynamic study of nonsynonymous single nucleotide polymorphisms associated with kidney stones in the SLC26A6 gene. J Urol 196(1):118–123. doi:10.1016/j.juro.2016.01.093 PubMedCrossRef

71.

Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS (2006) Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 38(4):474–478. doi:10.1038/ng1762 PubMedCrossRef

72.

Ferraro PM, D’Addessi A, Gambaro G (2013) When to suspect a genetic disorder in a patient with renal stones, and why. Nephrol Dial Transplant 28(4):811–820. doi:10.1093/ndt/gfs545 PubMedCrossRef

Title: Tubular and genetic disorders associated with kidney stones
Authors: Nilufar Mohebbi
Pietro Manuel Ferraro
Giovanni Gambaro
Robert Unwin
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Urolithiasis / Issue 1/2017
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-016-0945-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tubular and genetic disorders associated with kidney stones

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Histological aspects of the “fixed-particle” model of stone formation: animal studies

Physicochemical mechanisms of stone formation

The role of macromolecules in the formation of kidney stones

Do “inhibitors of crystallisation” play any role in the prevention of kidney stones? A critique

The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man

Accurate stone analysis: the impact on disease diagnosis and treatment